Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 17/20 | 0.82 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.78 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.78 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.78 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.78 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.78 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.78 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.78 |
| ▸ | BLM | P54132 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 1/20 | 0.73 |
| ▸ | LMNA | P02545 | 1/20 | 0.73 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.73 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.73 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.73 |
| ▸ | NPC1 | O15118 | 1/20 | 0.71 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.71 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.69 |
| ▸ | DRD4 | P21917 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL10417814 | 0.95 | BLM (0.81) | OPRK1OPRM1CYP3A4CYP2D6CYP2C9 | |
| Fumaric Acid SCHEMBL10417816 | 0.95 | BLM (0.81) | OPRK1OPRM1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8221863 | 0.90 | OPRK1 (1.00) | OPRK1OPRM1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL8221866 | 0.90 | OPRK1 (1.00) | OPRK1OPRM1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL9651995 | 0.90 | OPRK1 (0.81) | OPRK1OPRM1CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL5629280 | 0.89 | OPRK1 (0.79) | OPRK1OPRM1CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL10417791 | 0.89 | OPRK1 (1.00) | OPRK1OPRM1CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL5629714 | 0.89 | OPRK1 (0.98) | OPRK1OPRM1CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL5629721 | 0.89 | OPRK1 (0.98) | OPRK1OPRM1CYP3A4CYP2D6CYP2C9 | |
| Hydrochloric Acid SCHEMBL6359486 | 0.89 | OPRK1 (0.79) | OPRK1OPRM1CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2001015678-A2 | TOPICAL USE OF KAPPA OPIOID AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | claimed |
| US-6174878-B1 | OR INTRANASAL COMPOSITION E.G., ASIMADOLINE (EMD-61753), ENADOLINE, BENZENEACETAMIDE, AS AN ANALGESIC FOR EAR INFECTION, SWIMMER'S EAR, ETC.; ACTIVATION OF SPECIFIC RECEPTORS SO NO SIDE EFFECTS | ALCON LABORATORIES, INC. | 2001-01-16 | — | — | US | claimed |
| EP-2252581-B1 | KAPPA SELECTIVE OPIOID RECEPTOR ANTAGONIST | LILLY CO ELI (US) | 2012-06-20 | — | — | EP | disclosed |
| US-8173695-B2 | Kappa selective opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2012-05-08 | — | — | US | disclosed |
| US-20100197669-A1 | KAPPA SELECTIVE OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY (US) | 2010-08-05 | — | — | US | disclosed |
| US-7709522-B2 | Kappa selective opioid receptor antagonist | ELI LILLY AND COMPANY (US) | 2010-05-04 | — | — | US | disclosed |
| US-20090186873-A1 | KAPPA SELECTIVE OPIOID RECEPTOR ANTAGONIST | ELI LILLY AND COMPANY | 2009-07-23 | — | — | US | disclosed |
| WO-2001015678-A2 | TOPICAL USE OF KAPPA OPIOID AGONISTS TO TREAT OTIC PAIN | ALCON LABORATORIES, INC. (US) | 2001-03-08 | — | — | WO | disclosed |
| US-6174878-B1 | OR INTRANASAL COMPOSITION E.G., ASIMADOLINE (EMD-61753), ENADOLINE, BENZENEACETAMIDE, AS AN ANALGESIC FOR EAR INFECTION, SWIMMER'S EAR, ETC.; ACTIVATION OF SPECIFIC RECEPTORS SO NO SIDE EFFECTS | ALCON LABORATORIES, INC. | 2001-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090186873-A1 | KAPPA SELECTIVE OPIOID RECEPTOR ANTAGONIST | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885OPRM1 3/4885CYP3A4 3225/4885 |
| US-20100197669-A1 | KAPPA SELECTIVE OPIOID RECEPTOR ANTAGONIST | OPRK1, OPRD1, OPRM1 | OPRK1 1/4885OPRM1 3/4885CYP3A4 3225/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.